Condition: Cancer Survivors · Healthy Participant · Elderly · Sponsor: GI Innovation, Inc.
This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.
This description comes directly from the study's public registry record.
Wayne Lee, Ph.D., MBA · +82-2-404-2003 · woohyung.wayne.lee@gi-innovation.com
Karen Hwang · +82-2-404-2003
Always discuss trial participation with your own doctor first.
| Novatrials | Charlestown, New South Wales, Australia | Recruiting |
| Southern Oncology Clinical Research Unit | Adelaide, South Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07363057